Overview Dividends

(AGIO) Agios Pharm - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00847X1046

Mitapivat, Tebapivat, AG-181, AG-236

EPS (Earnings per Share)

EPS (Earnings per Share) of AGIO over the last years for every Quarter: "2020-09": -1.43, "2020-12": -1.41, "2021-03": 26.95, "2021-06": -1.44, "2021-09": -1.56, "2021-12": -1.74, "2022-03": -1.74, "2022-06": -1.68, "2022-09": -1.49, "2022-12": 0.67, "2023-03": -1.47, "2023-06": -1.51, "2023-09": -1.64, "2023-12": -1.72, "2024-03": -1.45, "2024-06": -1.69, "2024-09": -1.47, "2024-12": -1.74, "2025-03": -1.55, "2025-06": -1.93, "2025-09": -1.78,
EPS Growth (3y CAGR): -54.87%
EPS Trend (3y Corr): -54.7%
Last SUE: 0.04σ
Qual. Beats: 0

Revenue

Revenue of AGIO over the last years for every Quarter: 2020-09: 34.706, 2020-12: 44.045, 2021-03: 41.409, 2021-06: 37.347, 2021-09: 0, 2021-12: 4.141E-5, 2022-03: 0.832, 2022-06: 5.582, 2022-09: 3.516, 2022-12: 4.31, 2023-03: 5.609, 2023-06: 6.712, 2023-09: 7.399, 2023-12: 7.103, 2024-03: 8.189, 2024-06: 8.615, 2024-09: 8.964, 2024-12: 10.73, 2025-03: 8.726, 2025-06: 12.455, 2025-09: 12.88,
Revenue Growth (3y CAGR): 48.90%
Revenue Trend (3y Corr): 94.7%
Last SUE: 1.68σ
Qual. Beats: 2
Risk via 10d forecast
Volatility 173%
Value at Risk 5%th 260%
Relative Tail Risk -8.54%
Reward TTM
Sharpe Ratio -0.67
Alpha -65.38
Character TTM
Hurst Exponent 0.249
Beta 0.943
Beta Downside 0.809
Drawdowns 3y
Max DD 63.76%
Mean DD 24.21%
Median DD 22.17%

Description: AGIO Agios Pharm November 10, 2025

Agios Pharmaceuticals (NASDAQ: AGIO) is a Cambridge-based biopharma that focuses on targeting cellular metabolism. Its flagship product, PYRUKYND (mitapivat), is an oral activator of both wild-type and mutant pyruvate kinase and received FDA approval in 2022 for adults with pyruvate-kinase (PK) deficiency, a rare hemolytic anemia. The company is expanding PYRUKYND into several hematologic indications-including sickle-cell disease (Phase 3), pediatric PK deficiency, and both non-transfusion-dependent and transfusion-dependent α- or β-thalassemia-while also advancing a pipeline of metabolic-focused candidates such as tebapivat (myelodysplastic syndrome and hemolytic anemias), AG-181 (phenylketonuria), and an Alnylam-licensed siRNA (AG-236) for polycythemia vera.

From a financial standpoint, Agios reported FY 2023 revenue of roughly $71 million, a net loss of $327 million, and a cash runway of about $1.2 billion, giving it sufficient liquidity to fund its late-stage trials through at least 2026. The PK-deficiency market is estimated at $300 million globally, and broader hematology biotech has been benefitting from a 12 % CAGR in R&D spend, driven by advances in gene-editing and RNA-based therapies-trends that could amplify Agios’ addressable opportunity if its pipeline clears regulatory hurdles.

Given the high-risk, high-reward nature of late-stage metabolic therapeutics, investors should monitor FDA decision dates, enrollment metrics in the ongoing Phase 3 sickle-cell trial, and any partnership announcements that could de-risk commercialization; for a deeper, data-driven assessment of AGIO’s risk-adjusted upside, a quick look at ValueRay’s analytical dashboard may be worthwhile.

AGIO Stock Overview

Market Cap in USD 2,545m
Sub-Industry Biotechnology
IPO / Inception 2013-07-24
Return 12m vs S&P 500 -59.8%
Analyst Rating 4.0 of 5

AGIO Dividends

Currently no dividends paid

AGIO Growth Ratios

Metric Value
CAGR 3y -5.42%
CAGR/Max DD Calmar Ratio -0.09
CAGR/Mean DD Pain Ratio -0.22
Current Volume 7666.2k
Average Volume 647.4k

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-401.3m TTM) > 0 and > 6% of Revenue (6% = 2.69m TTM)
FCFTA -0.30 (>2.0%) and ΔFCFTA -11.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 2140 % (prev 2904 %; Δ -764.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.30 (>3.0%) and CFO -409.9m <= Net Income -401.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 13.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (58.1m) change vs 12m ago -0.50% (target <= -2.0% for YES)
Gross Margin 84.41% (prev 76.16%; Δ 8.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 2.82% (prev 1.83%; Δ 0.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -12.09 (EBITDA TTM -441.8m / Interest Expense TTM -37.0m) >= 6 (WARN >= 3)

Altman Z'' -3.10

(A) 0.69 = (Total Current Assets 1.03b - Total Current Liabilities 74.8m) / Total Assets 1.39b
(B) -0.33 = Retained Earnings (Balance) -453.7m / Total Assets 1.39b
(C) -0.28 = EBIT TTM -447.1m / Avg Total Assets 1.59b
(D) -4.45 = Book Value of Equity -451.5m / Total Liabilities 101.4m
Total Rating: -3.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 35.86

1. Piotroski 1.50pt
2. FCF Yield -25.30%
3. FCF Margin data missing
4. Debt/Equity 0.03
5. Debt/Ebitda 0.11
6. ROIC - WACC (= -41.29)%
7. RoE -28.35%
8. Rev. Trend 94.65%
9. EPS Trend -54.65%

What is the price of AGIO shares?

As of November 21, 2025, the stock is trading at USD 24.57 with a total of 7,666,207 shares traded.
Over the past week, the price has changed by -42.24%, over one month by -42.39%, over three months by -33.27% and over the past year by -55.02%.

Is AGIO a buy, sell or hold?

Agios Pharm has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy AGIO.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the AGIO price?

Issuer Target Up/Down from current
Wallstreet Target Price 47.3 92.6%
Analysts Target Price 47.3 92.6%
ValueRay Target Price 23.6 -4.1%

AGIO Fundamental Data Overview November 17, 2025

Market Cap USD = 2.55b (2.55b USD * 1.0 USD.USD)
P/E Forward = 2.4655
P/S = 56.8283
P/B = 1.9828
Beta = 0.836
Revenue TTM = 44.8m USD
EBIT TTM = -447.1m USD
EBITDA TTM = -441.8m USD
Long Term Debt = 44.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 18.0m USD (from shortTermDebt, last quarter)
Debt = 44.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -48.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.64b USD (2.55b + Debt 44.5m - CCE 952.9m)
Interest Coverage Ratio = -12.09 (Ebit TTM -447.1m / Interest Expense TTM -37.0m)
FCF Yield = -25.30% (FCF TTM -414.1m / Enterprise Value 1.64b)
FCF Margin = -924.5% (FCF TTM -414.1m / Revenue TTM 44.8m)
Net Margin = -895.9% (Net Income TTM -401.3m / Revenue TTM 44.8m)
Gross Margin = 84.41% ((Revenue TTM 44.8m - Cost of Revenue TTM 6.99m) / Revenue TTM)
Gross Margin QoQ = 86.96% (prev 76.23%)
Tobins Q-Ratio = 1.18 (Enterprise Value 1.64b / Total Assets 1.39b)
Interest Expense / Debt = 21.55% (Interest Expense 9.60m / Debt 44.5m)
Taxrate = -0.0% (0.0 / -103.4m)
NOPAT = -447.1m (EBIT -447.1m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 13.82 (Total Current Assets 1.03b / Total Current Liabilities 74.8m)
Debt / Equity = 0.03 (Debt 44.5m / totalStockholderEquity, last quarter 1.28b)
Debt / EBITDA = 0.11 (negative EBITDA) (Net Debt -48.2m / EBITDA -441.8m)
Debt / FCF = 0.12 (negative FCF - burning cash) (Net Debt -48.2m / FCF TTM -414.1m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = -28.96% (Net Income -401.3m / Total Assets 1.39b)
RoE = -28.35% (Net Income TTM -401.3m / Total Stockholder Equity 1.42b)
RoCE = -30.63% (EBIT -447.1m / Capital Employed (Equity 1.42b + L.T.Debt 44.5m))
RoIC = -31.59% (negative operating profit) (NOPAT -447.1m / Invested Capital 1.42b)
WACC = 9.70% (E(2.55b)/V(2.59b) * Re(9.49%) + D(44.5m)/V(2.59b) * Rd(21.55%) * (1-Tc(-0.0)))
Discount Rate = 9.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.99%
Fair Price DCF = unknown (Cash Flow -414.1m)
EPS Correlation: -54.65 | EPS CAGR: -54.87% | SUE: 0.04 | # QB: 0
Revenue Correlation: 94.65 | Revenue CAGR: 48.90% | SUE: 1.68 | # QB: 2

Additional Sources for AGIO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle